T. Rowe Price Associates
NUVL

T. Rowe Price Associates’s Nuvalent NUVL Stock Holding History

T. Rowe Price Associates’s Portfolio NUVL Stock Details NUVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.35M Sell
75,740
-1,980,393
-96% -$213M ﹤0.01% 1350
2026
Q1 		$211M Sell
2,056,133
-90,805
-4% -$9.25M 0.02% 451
2025
Q4 		$216M Buy
2,146,938
+336,518
+19% +$33.2M 0.02% 441
2025
Q3 		$157M Buy
1,810,420
+15,047
+0.8% +$1.19M 0.02% 515
2025
Q2 		$137M Buy
1,795,373
+344,771
+24% +$25.2M 0.02% 505
2025
Q1 		$103M Buy
1,450,602
+152,692
+12% +$11.9M 0.01% 546
2024
Q4 		$102M Buy
1,297,910
+215,633
+20% +$20.1M 0.01% 563
2024
Q3 		$111M Buy
1,082,277
+328,139
+44% +$27.2M 0.01% 545
2024
Q2 		$57.2M Sell
754,138
-104,023
-12% -$7.4M 0.01% 682
2024
Q1 		$64.4M Sell
858,161
-248,221
-22% -$19.8M 0.01% 654
2023
Q4 		$81.4M Buy
1,106,382
+299,446
+37% +$18.5M 0.01% 585
2023
Q3 		$37.1M Buy
806,936
+231,258
+40% +$10.3M 0.01% 768
2023
Q2 		$24.3M Sell
575,678
-11,182
-2% -$423K ﹤0.01% 887
2023
Q1 		$15.3M Buy
586,860
+51,174
+10% +$1.51M ﹤0.01% 982
2022
Q4 		$16M Buy
+535,686
New +$14.9M ﹤0.01% 972

Other funds holding NUVL

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

T. Rowe Price Associates's NUVL Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Nuvalent (NUVL) stake by 96% in Q2 2026, selling an estimated $213M and leaving 75,740 shares worth $9.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1350.

T. Rowe Price Associates first reported a position in NUVL in Q4 2022 and has held it in 15 quarters since. The position peaked at $216M in Q4 2025. 292 funds tracked by Wall St. Rank hold NUVL as of Q2 2026.

  • T. Rowe Price Associates held 75,740 shares of Nuvalent worth $9.35M as of Q2 2026.
  • T. Rowe Price Associates sold 1,980,393 Nuvalent shares in Q2 2026, an estimated $213M.
  • Nuvalent made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1350 holding.
  • T. Rowe Price Associates first reported a position in Nuvalent in Q4 2022 and has held it in 15 quarters since.
  • T. Rowe Price Associates's Nuvalent position peaked at $216M in Q4 2025.
  • 292 funds tracked by Wall St. Rank held Nuvalent as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.